Experience is irreplaceable, and achievements build reputation.
Beijing Gene MiNK Biotechnology Product Pipeline
| Product Pipeline | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| R&D Platform | Product Name | Application Direction | Product Progress | ||||||
| R&D | In Vitro | In Vivo | IIT | IND Approval | Clinical Phase I/II | Drug Launch | |||
| QM100 | QM101: Autologous NK cell injection | Advanced solid tumors in combination with PD-1 and other checkpoint inhibitors | 65% | ||||||
| QM102: Bispecific CAR-NK cell injection | Hematological malignancies: B-cell leukemia/lymphoma, various autoimmune diseases | 35% | |||||||
| QM103: Specific target CAR-NK cell injection | Hematological malignancies: Multiple myeloma, autoimmune diseases | 65% | |||||||
| QM105: Specific target CAR-NK cell injection | Solid tumors: Lung cancer, glioblastoma, etc. | 20% | |||||||
| QM200 | QM201: NKCE | Advanced solid tumors | 35% | ||||||
| QM202: NKCE | Hematological malignancies + Solid tumors | 20% | |||||||
Online Message
Please leave your needs and suggestions, and we will contact you as soon as possible!
Quick Navigation
Contact Information
Room 401, Unit 1, Building 2, No. 25, Jinghai Fourth Road, Beijing Economic and Technological Development Area, Beijing (Beijing Pilot Free Trade Zone, High-end Industrial Zone, Yizhuang Group)
Beijing Gene MiNK Biotechnology Co., Ltd
Business License